Project Name: AI-powered breast cancer diagnostic platform

Principal Investigator: KT Bae, T Tan, M Koohimoghadam

Technology

AI-powered breast cancer diagnostic platform utilizing deep learning algorithms for real-time mammogram analysis. Cloud-based SaaS solution delivering automated lesion segmentation, malignancy risk scoring (0-100%), and cancer progression prediction in few seconds. Purpose-built and validated on Asian population data, achieving 15-20% higher accuracy than Western-trained alternatives. Seamlessly integrates with existing hospital PACS systems via DICOM protocol.

Key Advantages

Population-Specific Accuracy: First AI platform optimized for Asian breast tissue characteristics and cancer patterns
Clinical Validation: Currently piloting in mainland China hospitals with real-world performance data
Rapid Deployment: Cloud-based infrastructure requires no specialized hardware investment
Proven Technology: Functional prototype demonstrating 90%+ accuracy on validation datasets
Regulatory Pathway: Clear route to medical device approval across Hong Kong, Macau, and Greater China
Market Gap Solution: Addresses critical shortage of radiologists while reducing diagnostic errors



Intellectual Property

Stage of Development

Current Stage: Pilot Testing & Market Validation
- ✅ Prototype developed and functional
- ✅ Pilot deployments active in mainland China hospitals
- ✅ Initial clinical feedback positive
- 🔄 Hong Kong database development (Phase 1)
- 🔄 Regulatory approval process initiated
- ⏭ Commercial launch planned (12-18 months)

Investment Use: HK$1.5M seed funding for Hong Kong market validation, database development, and regulatory approval.

Opportunities

Immediate Market (Year 1-2):
- Hong Kong: 200,000+ annual mammograms, HK$50-80M market
- Macau: Gateway to Greater China regulatory approval
- Mainland China expansion: Leveraging existing pilot partnerships

Revenue Potential:
- Per-scan licensing: HK$75-150 per analysis
- Institutional subscriptions: Tiered annual packages
- B2B data services for pharma/research

Strategic Value:
- Partnership with or possible acquisition target for medical imaging giants (Philips, GE, Siemens)

Contact

: baekt@hku.hk

HKU Med
LKS Faculty of Medicine
The University of Hong Kong
香港大學李嘉誠醫學院